CRISPR/Cas9 as a New Antiviral Strategy for Treating Hepatitis Viral Infections

Area of Science:

• Molecular Biology
• Hepatology
• Gene Editing Technologies

Background:

• Viral hepatitis, caused by HAV, HBV, HCV, HDV, and HEV, leads to over 1 million deaths annually.
• Chronic HBV and HCV infections can cause cirrhosis and hepatocellular carcinoma (HCC).
• Current treatments for viral hepatitis, including interferon-α and nucleoside inhibitors, have limitations in achieving complete cures and managing chronic infections.

Purpose of the Study:

• To review the application of CRISPR/Cas9 gene-editing technology in managing viral hepatitis.
• To explore novel drug development strategies for treating acute and chronic viral hepatitis.
• To summarize current knowledge on using CRISPR/Cas systems against hepatitis A, B, and C viruses.

Main Methods:

• CRISPR/Cas9 system enables targeted disruption of viral genomes or host factors involved in replication.
• Guide RNA directs the Cas9 enzyme to create double-strand DNA breaks at specific genomic sites.
• Review of existing research on CRISPR/Cas applications for hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

Main Results:

• CRISPR/Cas9 technology provides a versatile platform for antiviral therapeutic strategies.
• Potential for precise targeting of viral genetic material or host cell machinery crucial for viral replication.
• Highlights innovative approaches for drug development against challenging viral hepatitis infections.

Conclusions:

• CRISPR/Cas9 represents a groundbreaking advance in developing novel treatments for viral hepatitis.
• This technology holds promise for addressing both acute and chronic forms of hepatitis A, B, and C.
• Further research into CRISPR/Cas applications is crucial for advancing viral hepatitis therapeutics.